<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32824</article-id><article-id pub-id-type="doi">10.26442/terarkh2018908118-124</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Problems of nociception in gastroesophageal reflux disease: diagnostics and treatment of irritated oesophagus</article-title><trans-title-group xml:lang="ru"><trans-title>Проблемы ноцицепции при гастроэзофагеальной рефлюксной болезни: диагностика и лечение раздраженного пищевода</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sablin</surname><given-names>O A</given-names></name><name xml:lang="ru"><surname>Саблин</surname><given-names>Олег Александрович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф., зав. отд. терапии и профпатологии ФГБУ «Всероссийский центр экстренной и радиационной медицины им. А.М.Никифорова» МЧС России</p></bio><email>gastroleg@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ilchishina</surname><given-names>T A</given-names></name><name xml:lang="ru"><surname>Ильчишина</surname><given-names>Татьяна Алексеевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-гастроэнтеролог «СМ-клиника»</p></bio><email>ita17@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.M. Nikiforov Russian Center of Emergency and Radiation Medicine Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters</institution></aff><aff><institution xml:lang="ru">ФГБУ «Всероссийский центр экстренной и радиационной медицины им. А.М. Никифорова» МЧС России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">SM-clinic</institution></aff><aff><institution xml:lang="ru">«СМ-клиника»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2018</year></pub-date><volume>90</volume><issue>8</issue><issue-title xml:lang="en">VOL 90, NO8 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 90, №8 (2018)</issue-title><fpage>118</fpage><lpage>124</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32824">https://ter-arkhiv.ru/0040-3660/article/view/32824</self-uri><abstract xml:lang="en"><p>The following factors of gastroesophageal reflux disease (GERD) pathogenesis are addressed in the abstract: activation of nociceptors, hyperexpression of pro-inflammatory cytokines and increase of functional activity of immune competent cells. The current classification of GERD is given which is based on identification of 4 phenotypes of the disease according to diagnostic criteria and prognosis of treatment effectiveness. Importance of pH-impedance monitoring in GERD diagnostics is demonstrated based on its primary significance for identification of reflux nature and determination of relationship between GERD symptoms and reflux. The diagnostics criteria of functional heartburn and hypersensitive oesophagus according to Rome IV criteria (2016) are presented. The data of the private investigation are demonstrated according to which irritated oesophagus was observed in 26.2% of healthy persons and in 24.2% of GERD patients with endoscopic or pH-metric symptoms of the disease. Implication of oesophagus clearance disorder in GERD pathogenesis has been pointed out. An overview of the current literature data about effectiveness of surgical treatment in patients with different GERD phenotypes and also assessment of clinical effectiveness of long-term treatment with PPI are given. Advantages of anti-secretory drug of the last generation rabeprazole in different patient groups and possibilities of its use in all GERD phenotypes have been discussed.</p></abstract><trans-abstract xml:lang="ru"><p>В статье рассматриваются такие факторы патогенеза симптомов при гастроэзофагеальной рефлюксной болезни (ГЭРБ), как активация ноцицепторов, гиперэкспрессия провоспалительных цитокинов и повышение функциональной активности иммунокомпетентных клеток. Приведена современная классификация ГЭРБ, основанная на выделении четырех фенотипов заболевания по диагностическим критериям и прогнозу эффективности лечения. Показана значимость рН-импедансометрии пищевода для диагностики фенотипов ГЭРБ по выраженности рефлюкса и связи симптомов с рефлюксом. Представлены диагностические критерии функциональной изжоги и гиперсенситивного пищевода согласно Римским критериям IV пересмотра (2016). Приведены данные собственных исследований, согласно которым раздраженный пищевод наблюдался у 26,2% здоровых лиц и у 24,2% больных ГЭРБ с эндоскопическими или рН-метрическими проявлениями заболевания. Подчеркнута роль нарушения клиренса пищевода в патогенезе ГЭРБ. Приводится обзор современных данных литературы об эффективности хирургического лечения у пациентов с различными фенотипами ГЭРБ, а также оценка клинической эффективности длительного применения ингибиторов протонной помпы. Обсуждаются преимущества антисекреторного препарата последнего поколения рабепразола у разных категорий больных и возможности его применения при различных формах ГЭРБ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>course of gastroesophageal reflux disease</kwd><kwd>prognosis of treatment effectiveness</kwd><kwd>hypersensitive</kwd><kwd>irritable oesophagus</kwd><kwd>functional heartburn</kwd><kwd>pH-impedance monitoring</kwd><kwd>proton pump inhibitors</kwd><kwd>rabeprazole</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>течение</kwd><kwd>прогноз эффективности лечения гастроэзофагеальной рефлюксной болезни</kwd><kwd>гиперсенситивный</kwd><kwd>раздраженный пищевод</kwd><kwd>функциональная изжога</kwd><kwd>pH-импедансометрия</kwd><kwd>ингибиторы протонной помпы</kwd><kwd>рабепразол</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bredenoord A.J. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol. 2012;107:8-15.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sifrim D, Fornari F. Esophageal impedance - pH monitoring. Dig Liver Dis. 2008;40:161-166.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Villa N, Vela M.F. Impedance - pH testing. Gastroenterol Clin N Am. 2013;42:17-26.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Saleh.C.MG, Smout J.P.M, Bredenoord A.J. The diagnosis of gastro - esophageal reflux disease cannot be made with barium esophagograms. Neurogastroenterol Motil. 2015;27:195-200.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Namiot Z, Sarosiek J, Marcinkiewicz M, et al. Declined human esophageal mucin secretion in patients with severe reflux esophagitis. Dig Dis Sci. 1994;39:2523-2529.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Niv Y, Fass R. The role of mucin in GERD and its complications. Gastroenterol Hepatol. 2011;9(1):55-59.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Van Roon A.H.C, Mayne G.C, Wijnhoven B.P.L, et al. Impact of gastro - esophageal reflux on mucin mRNA expression in the esophageal mucosa. J Gastrointest Surg. 2008;12:1331-1340.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Emerenziani S, Sifrim D, Habib F.J, et al. Presence of gas in the refluxate enhances reflux perception in non - erosive patients with physiological acid exposure of the oesophagus. Gut. 2008;57:443-447.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Aziz Q, Fass R, Gyawali C.P, et al. Functional Esophageal Disorders. Gastroenterology. 2016;150:1368-1379.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Altomare A, Guarino M, Cicala M, et al. Gastrointestinal sensitivity and gastrointestinal reflux disease. Ann NY Acad Sci. 2013;1300:80-95.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sugiura T, Tominaga M, Katsuya H, Mizumura K. Bradykinin low - ered the threshold temperature for heat activation of vanilloid receptor. J Neurophysiol. 2002;88:544-548.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rosenbaum T, Gordon-Shaag A, Munari M., Gordon S.E. Ca2+ /calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol. 2004;123:53-62.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Shaheen N.J, Falk G.W, Iyer P.G, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;111(1):30-50.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Boeckxstaens G, El-Serag H. Republished: Symptomatic reflux disease: the present, the past and the future. Postgrad Med J. 2015;91:46-54.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Саблин О.А. Гастроэзофагеальная рефлюксная болезнь и ее внепищеводные проявления: современные представления о диагностике и лечении. Автореф. дис. … докт. мед. наук. Санкт-Петербург; 2004. 45 с.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Patel A, Sayuk G.S, Kushnir V.M, Chan W.W, Gyawali C.P. GERD phenotypes from pH-impedance monitoring predict symptomatic outcomes on prospective evaluation. Neurogastroenterol Motil. 2016;28(4):513-521.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dent J, Armstrong D, Delaney B, Moayyedi P, Talley N.J, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004;53 Suppl. 4:1-24.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kirchheiner J, Glatt S, Fuhr U, Klotz U, et al. Relative potency of proton - pump inhibitors - comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19-31.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Di Mario F, Panozzo M.P, Baldassarre G, et al. The branded proton pump inhibitors (PPIs) increase levels of gastrin 17 (G-17) more than the generic ones in dyspeptic patients from an italian primary care population. Abstracts of the 23rd National Congress of Digestive Diseases. Dig Liver Dis. 2017;49S2:e73-e223.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Маев И.В., Трухманов А.С., Кучерявый Ю.А. Фармакоэкономика кислотозависимых заболеваний. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;(3):68-76.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Barnett J.L, Robinson M. Optimizing acid - suppression therapy. Manag Care. 2001;10(10):17-21.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Samer C.F, Lorenzini K, Rollason V, et al., Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther. 2013;17:165-184.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716-726.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):75-95.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Barrison A.F, Jarbe L.A, Weinberg M.D, et al. Patterns of proton pump inhibitors in clinical practice. Am J Med. 2001;111:469-473.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Gunaratnam N.T, Jessup T.P, Inadomi J. Sub - optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2006;23: 1473-7.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Pezanoski J, Guanaratnam N, Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms. Gastroenterology. 2003;124 Suppl.:128.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double - blind, placebo - controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non - erosive reflux disease. Aliment Pharmacol Ther. 2011;33(2):213-224.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Sarosiek I, Olyaee M, Majewski M, et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci. 2009;54(10):2137-2142.</mixed-citation></ref></ref-list></back></article>
